CancerNetwork Members: Login | Register
 

 
NEWS

New Way to Predict Prostate Cancer Severity—Size of Prostate
February 1, 2012
Long-Term Study Finds Vitamin E Supplements Raise the Risk of Prostate Cancer
ONCOLOGY,  October 13, 2011
PSA Screening for Prostate Cancer Put Into Question By the U.S. Preventive Services Task Force
October 10, 2011
EMCC: Radium-223 Plus Chemo Shows Clear OS Benefit
ONCOLOGY,  September 29, 2011
FDA Approves Denosumab for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer
September 23, 2011


 
PRACTICE GUIDELINES
Guide to Clinical Preventive Services, 2010-2011: Section 2
www.ahrq.gov -
National Guideline Clearinghouse | Screening for prostate cancer in U.S. men: ACPM position statement on preventive practice.
www.guidelines.gov -
0493 Prostate Cancer Patient Guideline NEW COPY:Layout 1
www.auanet.org -
 
JOB LISTINGS

Post a job

Powered by SearchMedica Jobs

 

Order Your Copy!
(2010, 13th Edition)

 


 

Please allow 3 – 4 weeks to ship
 
CONNECT WITH US
Become a fan on
Facebook
Add us on
Google Plus
Follow us on
Twitter
Sign up for our
Newsletters
Subscribe to our
RSS Feed

Prostate Cancer
 
REVIEW ARTICLES

Optimizing Outcomes of Advanced Prostate Cancer: Drug Sequencing and Novel Therapeutic Approaches
E. David Crawford, MD1, Thomas W. Flaig, MD1 , January 17, 2012

We have entered a period of accelerated drug development and optimism in the care of advanced prostate cancer. The treatment paradigm for these patients is rapidly evolving, with future study needed to define the optimal sequencing and potential combinations of these new agents.
• Sequencing of Therapies in Advanced Prostate Cancer
• What to Order From the Prostate Cancer Treatment Menu?

Evolution of Treatment Options for Patients With CRPC and Bone Metastases: Bone-Targeted Agents That Go Beyond Palliation of Symptoms to Improve Overall Survival
Kyle O. Rove, MD1, E. David Crawford, MD1 , December 31, 2011

This review will examine agents with potential activity in the palliation and treatment of skeletal metastases of PCa, and will weigh the clinical-outcomes evidence for and against their broad use.
• Managing CRPC: Improving Symptoms, Survival, or Both?
• Are We Trumping Bone Disease in Prostate Cancer?

Proton Therapy for Prostate Cancer
Bradford Hoppe, MD, MPH1, Randal Henderson, MD, MBA1, William M. Mendenhall, MD1, Romaine C. Nichols, MD1, Zuofeng Li, PhD1, Nancy P. Mendenhall, MD1 , June 15, 2011

PT is a promising treatment option for prostate cancer patients. Studies have already demonstrated extremely low rates of grade > 3 GU and GI toxicities and extremely high disease control, presumably related to improved radiation dose distributions over what can be achieved with IMRT.
• Proton Therapy for Prostate Cancer: Show Me the CER!
• Back to the Future: a Proton Pro/Con

Evolving Therapeutic Paradigms for Advanced Prostate Cancer
Joshua M. Ruch, MD1,Maha H. Hussain, MD, FACP1,2 , May 16, 2011

A threshold has clearly been crossed in the management of advanced prostate cancer; however, the impact on survival has been relatively modest, and efforts at personalized therapy have lagged behind those for other solid tumors.
• Advanced Prostate Cancer: New Agents, New Questions
• What's Needed to Make Optimal Use of the New Treatments

Screening for Prostate Cancer With PSA Testing: Current Status and Future Directions
Jennifer M. Croswell, MD, MPH1, Barnett S. Kramer, MD, MPH2, E. David Crawford, MD3 , May 12, 2011

This article presents a review of the literature on screening for prostate cancer with PSA testing; we include a detailed discussion of potential explanations for the contradictory results of the two largest randomized trials as well as reflections on the future of prostate cancer screening.
• Benefits and Pitfalls of Prostate Cancer Screening
• Preventing Prostate Cancer Overdiagnosis From Becoming Overtreatment

 
 
IMAGE IQ

Core Biopsy of Prostate From an Elderly Male
June 3, 2011

Core biopsy of prostate from an elderly male. Your diagnosis is:

 
JOURNAL SCAN
JMIR-Improving Access to Information and Support for Patients With Less Common Cancers: Hematologic Cancer Patients’ Views About Web-Based Approaches | Paul | Journal of Medical Internet Research
www.jmir.org - 12/21/11
Improving Access to Information and Support for Patients With Less Common Cancers: Hematologic Cancer Patients Views About Web-Based Approaches|Background: Meeting the psychosocial needs of vulnerable groups such as cancer survivors remains an ongoing challenge. This is particularly so for those who have less access to the usual forms of medical specialist and in-person support networks. Internet-based approaches offer an opportunity to better meet patients information and support needs by overcoming
Genome Medicine | Full text | Embryonic stem cell-specific signatures in cancer: insights into genomic regulatory networks and implications for medicine
genomemedicine.com - 11/29/11
Embryonic stem (ES) cells are of great interest as a model system for studying early developmental processes and because of their potential therapeutic applications in regenerative medicine. Obtaining a systematic understanding of the mechanisms that control the 'stemness' - self-renewal and pluripotency - of ES cells relies on high-throughput tools to define gene expression and regulatory networks at the genome level. Such recently developed systems biology approaches have revealed highly interconnected
A quarter of patients with cancer see their GP several times before being referred | BMJ
www.bmj.com - 11/24/11
NotesCite this as: BMJ 2011;343:d7601
British Journal of Cancer - Abstract of article: DNA methylation profiles delineate epigenetic heterogeneity in seminoma and non-seminoma
www.nature.com - 11/8/11
The BJC is owned by Cancer Research UK, a charity dedicated to understanding the causes, prevention and treatment of cancer and to making sure that the best new treatments reach patients in the clinic as quickly as possible. The journal reflects these aims. It was founded more than fifty years ago and, from the start, its far-sighted mission was to encourage communication of the very best cancer research from laboratories and clinics in all countries. The breadth of its coverage, its editorial independenc
WJSO | Full text | Residual tumor after the salvage surgery is the major risk factors for primary treatment failure in malignant ovarian germ cell tumors: A retrospective study of single institution.
www.wjso.com - 10/11/11
Malignant ovarian germ cell tumors are rare, and knowledge of their prognostic factors is limited, with little available randomized data. This study was conducted to evaluate the clinicopathologic characteristics of malignant ovarian germ cell tumors and to determine the association of their prognostic factors to primary treatment failure.|Malignant ovarian germ cell tumors are rare, and knowledge of their prognostic factors is limited, with little available randomized data. This study was conducted to eva

Result Pages: 1 2 3 4 5 6 Next


 
MEDLINE
Histone deacetylase inhibitor valproic acid suppresses the growth and increases the androgen responsiveness of prostate cancer cells.
pubmed.gov - 12/8/11
We identified the molecular target by histone deacetylase (HDAC) inhibitors for exploring their potential prostate cancer (PCa) therapy. Upon HDAC inhibitors-treatment, LNCaP cell growth was suppressed, correlating with increased cellular prostatic acid phosphatase (cPAcP) expression, an authentic protein tyrosine phosphatase. In those cells, ErbB-2 was dephosphorylated, histone H3/H4 acetylation and methylation increased and cyclin proteins decreased. In PAcP shRNA-transfected C-81 cells, valproic acid (VPA) efficacy of growth suppression was diminished. Further, VPA pre-treatment enhanced androgen responsiveness of C-81, C4-2 and MDA PCa2b-AI cells. Thus, cPAcP expression is involved in growth suppression by HDAC inhibitors in PCa cells, and VPA pre-treatments increase androgen responsiveness.
Association of tissue promoter methylation levels of APC, TGF2, HOXD3 and RASSF1A with prostate cancer progression.
pubmed.gov - 11/15/11
Aberrant promoter methylation is known to silence tumor-suppressor genes in prostate cancer (PCa). We correlated quantitative promoter methylation levels of APC, TGF2 and RASSF1A in 219 radical prostatectomies diagnosed between 1998 and 2001 with clinicopathological follow-up data available including Gleason Pattern (GP), Gleason Score (GS) and pathological stage and explored their potential in predicting biochemical recurrence using univariate and multivariate analyses. We observed that the average methylation levels of APC increased significantly from GS 6 to GS7, and pT2 to pT3a, and that of TGF2 increased from GS 6 to GS7, but not for RASSF1A. PCa samples were also stratified into high methylation (HM) and low methylation (LM) groups based on the PMR scores of all cases analyzed for each marker. The HM frequency of APC was greater in pT3a than pT2, and in GS 8 than GS 6. The HM frequency also increased significantly from GP3 to GP4 for APC, TGF2 and RASSF1A.
Genome-wide linkage scan for prostate cancer susceptibility in Finland: evidence for a novel locus on 2q37.3 and confirmation of signal on 17q21-q22.
pubmed.gov - 11/15/11
Genome-wide linkage studies have been used to localize rare and highly penetrant prostate cancer (PRCA) susceptibility genes. Linkage studies performed in different ethnic backgrounds and populations have been somewhat disparate, resulting in multiple, often irreproducible signals because of genetic heterogeneity and high sporadic background of the disease. Our first genome-wide linkage study and subsequent fine-mapping study of Finnish hereditary prostate cancer (HPC) families gave evidence of linkage to one region. Here, we conducted subsequent scans with microsatellites and SNPs in a total of 69 Finnish HPC families. GENEHUNTER-PLUS was used for parametric and nonparametric analyses. Our microsatellite genome-wide linkage study provided evidence of linkage to 17q12-q23, with a heterogeneity LOD (HLOD) score of 3.14 in a total of 54 of the 69 families. Genome-wide SNP analysis of 59 of the 69 families gave a highest HLOD score of 3.40 at 2q37.3 under a dominant high penetrance model.
Radiotherapy and androgen deprivation for prostate cancer.
pubmed.gov - 10/6/11
Re: Coffee consumption and prostate cancer risk and progression in the health professionals follow-up study.
pubmed.gov - 10/5/11

Result Pages: 1 2 3 4 5 6 Next


 
CLINICAL TRIALS
Anxiety in Black Men With Prostate Cancer: Validation of the Memorial Anxiety Scale for Prostate Cancer in an Sample of Black Men - Full Text View - ClinicalTrials.gov
www.clinicaltrials.gov -
Lycopene in Preventing Prostate Cancer in Patients Who Are at High Risk of Developing Prostate Cancer - Full Text View - ClinicalTrials.gov
www.clinicaltrials.gov -
Isoflavone in Prostate-specific Antigen Recurrent Prostate Cancer - Full Text View - ClinicalTrials.gov
www.clinicaltrials.gov -
Selenium and Prostate Cancer: Clinical Trial on Availability to Prostate Tissue and Effects on Gene Expression - Full Text View - ClinicalTrials.gov
www.clinicaltrials.gov -
Polyunsaturated Fatty Acids in Treating Patients With Prostate Cancer Undergoing Prostate Biopsy and/or Surgery - Full Text View - ClinicalTrials.gov
www.clinicaltrials.gov -

Result Pages: 1 2 3 4 5 6 Next




 
   SEARCH MEDICA RX
   Browse drugs by name:
A B C D E F G H I J
K L M N O P Q R S T
U V W X Y Z All      
   Search for drugs:
Search

 
 
FROM PHYSICIANS PRACTICE
Tax Schemes Every Physician Should Avoid
Ike Devji, JD, January 31, 2012
The next 60 days marks the final push to sell physicians across the United States tax plans of both good and questionable value.
Boosting Collections at Your Medical Practice: Whose Job Is It?
P.J. Cloud-Moulds, January 28, 2012
Embrace the relationship between your billing company and your medical practice staff.
Managing Difficult Medical Practice Employees
Shelly K. Schwartz, January 27, 2012
Tips for transforming immature staff members into great employees.
Prevent Physician Distraction When Using mHealth Technology
Aubrey Westgate, January 25, 2012
As more and more physicians use handheld mobile technology in their day-to-day work, some critics are raising concerns about “distracted doctoring.”
Can That Applicant Do the Job at Your Medical Practice?
Karen Zupko, January 25, 2012
If like many communities, yours has significant numbers of non-English speaking people with whom neither you nor your staff are able to converse, your practice is at a serious disadvantage.
 
MOST POPULAR
 
COMMENTS